Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.030.02%
QQQ
709.410.03%
BTC/USD
78297.021.9494%
DIA
524.750.05%
GLD
393.500.17%
TLT
80.93-

Avalyn Pharma Inc

AVLNNASDAQ
Trade with Public
Trade with Public
$34.98
1.414.2%
At close: Sep 14, 5:00 PM EST
$34.98
N/A
After Hours: 4:00 PM EST
OverviewNewsEventsFinancialsSentimentOwnershipCompareOptionsStock Report

Avalyn Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Avalyn Pharma (AVLN).

Price Target Range — 2 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$63Upside to Avg. PT+79.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026Morgan StanleyJudah FrommerPT RaiseOverweight$53→$57
May 26, 2026Evercore ISI GroupGavin Clark-GartnerInitiateOutperform$51
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.
Benzinga Newsdesk

This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Top Wall Street analysts upgraded LEA, BAH, TRV, and CGNX stocks, with higher price targets. See what analysts think of other stocks on rating page.
Avi Kapoor

PRO
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $51.
Benzinga Newsdesk

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
Avi Kapoor

PRO
Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80

Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.
Benzinga Newsdesk

PRO
Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53

Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved